^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ovarian Cancer
    Drug:Yondelis (trabectedin) (Alkylating agent, DNA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    09/17/2007
    Excerpt:
    Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
    Secondary therapy:
    pegylated liposomal doxorubicin